Neprilysin Gene Transfer Reduces Amyloid-Beta Levels and Improves Cognitive Function in Alzheimer’s Animal Models

A recent study published in *BMC Neuroscience* reports findings on the potential therapeutic effects of neprilysin gene transfer in animal models of Alzheimer’s disease. Researchers observed that introducing the neprilysin gene led to a reduction in amyloid-beta (Abeta) levels, a protein associated with Alzheimer’s pathology, and improved behavioral outcomes in the tested subjects. The study highlights the role of neprilysin, an enzyme known for breaking down Abeta peptides, as a promising target for addressing neurodegenerative conditions.

The research focused on assessing how neprilysin gene transfer impacts both biochemical markers and cognitive functions in animal models. Results showed significant decreases in Abeta accumulation following the gene transfer intervention. Additionally, animals demonstrated enhanced performance in behavioral tests designed to measure memory and learning capabilities. These findings suggest that increasing neprilysin activity through genetic modification may influence key factors contributing to Alzheimer’s progression while simultaneously improving cognitive function. Further studies are expected to explore its long-term efficacy and potential applications for human treatment strategies.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: November 30, 2025

Related posts:

Japan’s MHLW Approves GSK’s Blenrep for Combination Therapy in Advanced Multiple Myeloma Treatment Diminishing US Scientific Workforce Threatens Pharmaceutical Innovation and Healthcare Progress Gilead Sciences Partners with PEPFAR to Provide Twice-Yearly HIV Prevention Injection to Over 2 Million in Resource-Limited Countries Lifecore Biomedical and PolyPeptide Laboratories Partner to Offer Integrated Peptide Manufacturing for U.S. Pharma

Author

GOAI